Phaim Pharma
We are developing a novel therapeutic platform, known as Antigenic Immune Modulation (AIM), designed to cure, improve, halt or prevent autoimmune disease.
Our first application is Type 1 Diabetes (T1D), with a pipeline that includes psoriasis, rheumatoid arthritis and multiple sclerosis.
